The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy (Q39201898)

9 September 2017

title

The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy (English)

1 reference

adaptive radiation therapy

9 September 2017

main subject

0 references

author

Fredrik Wärnberg

7

1 reference

9 September 2017

3

Karin Jirström

1 reference

9 September 2017

Wenjing Zhou

6

0 references

Signe Borgquist

object named as

Signe Borgquist

8

0 references

author name string

Salma Butt

1

1 reference

9 September 2017

Talha Butt

2

1 reference

9 September 2017

Linda Hartman

4

1 reference

9 September 2017

Rose-Marie Amini

5

1 reference

9 September 2017

publication date

29 April 2014

1 reference

Annals of Surgical Oncology

9 September 2017

published in

1 reference

9 September 2017

volume

21

1 reference

9 September 2017

issue

9

1 reference

9 September 2017

page(s)

2911-2919

1 reference

Epidemiology of Ductal Carcinoma In Situ

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Is DCIS breast cancer, and how do I treat it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Targeting tumor cell metabolism with statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Statins and cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Novel aspects of mevalonate pathway inhibitors as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Optimization of a heterologous mevalonate pathway through the use of variant HMG-CoA reductases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

Risk of subsequent invasive breast cancer after breast carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3708-4

10.1245/S10434-014-3708-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

9 September 2017

1027859063

0 references

1 reference